Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Carfilzomib
Related studies linked through entity extraction aliases.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Carfilzomib and Belatacept for Desensitization
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Status
- SUSPENDED
- Phase
- PHASE2
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
KRDI in Transplant-Eligible MM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Status
- RECRUITING
- Phase
- PHASE2
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3